🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,071 results for “tablet” Clear

  1. Lusutrombopag Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Idiopathic Thrombocytopenic Purpura

    phase 2 small molecule completed

    1 trial

  2. Lynparza 100 mg film-coated tablets, CYCLOPHOSPHAMIDE, Lynparza 150 mg film-coated tablets, DOCETAXEL, DOXORUBICIN, CARBOPLATIN, EPIRUBICIN

    Shanghai Reinovax Biologics Co.,LTD

    Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)

    phase 2 small molecule active

    1 trial

  3. Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Faslodex 250 mg solution for injection., Lynparza 150 mg film-coated tablets, Zoladex 3.6 mg Implant

    Ningbo Cancer Hospital

    ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.

    phase 2 small molecule active

    1 trial

  4. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    Fondazione Telethon ETS

    BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer

    phase 2 small molecule active

    1 trial

  5. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    Wuhan Createrna Science and Technology Co., Ltd

    Basket tumors

    phase 2 small molecule active

    1 trial

  6. Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions

    phase 2 small molecule active

    1 trial

  7. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Fondazione Telethon ETS

    recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes

    phase 2 small molecule active

    1 trial

  8. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Verona Pharma Ireland Limited

    Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy

    phase 2 small molecule active

    1 trial

  9. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, ART6043, ART6043, ART6043, ART6043, ART6043

    Lacuna Pharma Pty Ltd

    Metastatic solid tumors, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  10. Lytgobi 4 mg film-coated tablets, 5-FU medac 50 mg/ml, Injektionslösung, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tevimbra 100 mg concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  11. M1774, M1774, M1774, M1774, M4076, Zejula 100 mg film-coated tablets

    Merck Sharp and Dohme

    Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy

    phase 2 small molecule active

    1 trial

  12. MERCAPTOPURINE, PREDNISONE, VINCRISTINE SULFATE, CYTARABINE, FILGRASTIM, LENOGRASTIM, CYTARABINE, IDARUBICIN HYDROCHLORIDE, FOLINIC ACID, Iclusig 15 mg film-coated tablets, METHYLPREDNISOLONE SODIUM SUCCINATE, CYCLOPHOSPHAMIDE, METHOTREXATE, METHOTREXATE, DEXAMETHASONE DISODIUM PHOSPHATE, Iclusig 15 mg film-coated tablets

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.

    phase 2 small molecule active

    1 trial

  13. MIDAZOLAM , ODM-208 100 mg Tablet, ODM-208 50 mg Tablet, ODM-208 25 mg Tablet, ODM-208 5 mg film-coated tablet

    Orion Laboratories Pty.

    Metastatic castration-resistant prostate cancer.

    phase 2 small molecule active

    1 trial

  14. ML-004 (IR)/(ER) tablet

    MapLight Therapeutics

    Autism Spectrum Disorder

    phase 2 small molecule active

    2 trials

  15. Matching Placebo tablets without active substance, BIIB122

    Biogen

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  16. Matching film-coated placebo tablet

    Bioprojet Pharma

    Obsessive compulsive disorder

    phase 2 small molecule active

    1 trial

  17. Matching orodispersible placebo tablet

    Bioprojet Pharma

    Eosinophilic esophagitis

    phase 2 small molecule active

    1 trial

  18. Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen

    Boehringer Ingelheim

    Crohn`s Disease (CD)

    phase 2 small molecule active

    1 trial

  19. Mekinist 0.5 mg film-coated tablets

    Disc Medicine

    Neurofibromatosis type 1

    phase 2 small molecule active

    1 trial

  20. Mekinist 2 mg film-coated tablets, Hydroxychloroquine sulfate Accord 200mg film-coated tablets, Mekinist 0.5 mg film-coated tablets

    Ningbo Cancer Hospital

    Metastatic refractory Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  21. Mektovi 15 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules

    Ningbo Cancer Hospital

    BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)

    phase 2 small molecule active

    1 trial

  22. Mektovi 15 mg film-coated tablets, Tyverb 250 mg film-coated tablets, Vinorelbine Accord 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)

    phase 2 small molecule active

    1 trial

  23. Memantine Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation Disease

    phase 2 small molecule active

    1 trial

  24. Metformin Zentiva 500 mg Filmtabletten

    The George Institute

    Multidrug rezistant pulmonary tuberculosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources